GM101 injection for advanced Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests an investigational gene therapy injection called GM101 for people with advanced Parkinson's disease whose symptoms are not well controlled by standard medications. The study will see if this treatment can help improve movement and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 70 years old.
- You have had Parkinson's disease for at least 5 years.
- Your Parkinson's symptoms are severe (Hoehn-Yahr stage 4-5) when you are off medication.
- Current medications do not control your symptoms well, or you have bad side effects from them.
- You are willing to undergo a surgical procedure and imaging tests like CT or MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for Parkinson's disease in people who have a specific genetic change (GBA1 mutation) that may be causing their symptoms. The treatment aims to fix the root cause by delivering a corrected gene to the brain, which might help improve motor symptoms and reduce 'off' time.
This trial tests an experimental gene therapy injected directly into the brain, designed for people with Parkinson's disease who carry a specific genetic change called GBA1. The goal is to see if the treatment is safe, tolerable, and helps improve motor symptoms.
This trial tests a new gene therapy delivered directly into the brain to help control Parkinson's symptoms. It is for people with advanced Parkinson's disease who still have significant movement problems despite their current medications.
This trial tests a new gene therapy that may improve movement control in people with Parkinson's disease. It involves a one-time surgical injection into the brain and requires you to be off your usual Parkinson's medications during some assessments.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.